Overview
Lipopeptide, also known as Palmitoyl Hexapeptide-12, is a synthetic fatty acid-conjugated peptide consisting of a 16-carbon palmitic acid chain attached to a sequence of six amino acids — valine, glycine, valine, alanine, proline, and glycine. This type of molecule belongs to the broader class of lipopeptides, which are compounds that combine a lipid component with a peptide chain, a structural feature that influences how they interact with biological membranes and cellular systems. Lipopeptides also occur naturally in microorganisms, where they play roles in signaling and immune recognition, and the structural similarities between synthetic and naturally derived lipopeptides make them useful tools for studying biological processes in laboratory settings. Palmitoyl Hexapeptide-12 has a molecular weight of approximately 737 Da and has been studied in research contexts related to immune response, antigen presentation, and antimicrobial activity. This compound is intended strictly for research purposes and is not approved for human use or consumption.
Research & Bioactivity
Researchers have studied lipopeptides extensively in the context of antimicrobial activity, immune modulation, and drug delivery, with investigations spanning both in vitro systems and animal models. Studies have examined the role of lipopeptides such as colistin (polymyxin E) in combating multidrug-resistant gram-negative bacteria, including extensively drug-resistant Pseudomonas aeruginosa, with research conducted in rabbit models of keratitis exploring combination therapy approaches. Research has also investigated the relationship between aerosolized lipopeptide antibiotic use in intensive care settings and the emergence of bacterial resistance, using time-series analyses of clinical data. In the area of immunology, studies have examined how lipopeptide antigens are recognized by the immune system, with particular attention to CD1a-mediated antigen presentation and the activation of T cell responses in the context of infectious disease such as leprosy. Additionally, researchers have explored lipoproteins — lipid-modified peptide structures — as candidate components in vaccine development, studying their self-adjuvanting properties and the analytical challenges posed by their complex lipid modifications. Research has further investigated strategies for enhancing the delivery of lipopeptide-based compounds across mucosal barriers, using polymer carrier systems evaluated in artificial pulmonary mucus models.
Published Research
Enhanced Efficacy of Cefiderocol With PolyTrim Combination Therapy in a Rabbit Model of Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis.
Romanowski EG, Young EK, Mandell JB, Dhaliwal DK, Mammen A, et al. — 2026
PURPOSE: The 2023 Pseudomonas aeruginosa keratitis outbreak linked to contaminated artificial tears underscored the need for new therapies against extensively drug-resistant ocular pathogens. In vitro data suggested additive or synergistic activity between the siderophore-cephalosporin cefiderocol (FDC) and either moxifloxacin (MOX) or polymyxin B sulfate (PB). Here, we tested whether combining FDC with the commercial formulations of MOX (0.5%) or PolyTrim (PT; PB 10,000 U/mL + trimethoprim 0.1%) improved in vivo outcomes. METHODS: New Zealand White rabbits were injected intrastromally with 5000 CFU of Pseudomonas aeruginosa strain CDC1270. After 16 hours, established infections were treated every 30 minutes for 8 hours with FDC, followed 5 minutes later by MOX or PT. Additional groups received monotherapies or saline. Bacterial burden (CFU/cornea) and anterior chamber cultures were determined, and ocular inflammation was assessed. RESULTS: FDC + MOX reduced bacterial burden by 2.8 log10 CFU, outperforming FDC and MOX monotherapies, although no eyes were sterilized. PT monotherapy produced a significant 3.2 log10 reduction in CFU. The FDC + PT combination yielded the most potent activity, with almost 6.9 log10 reduction and sterilization of 10 of 12 corneas. Notably, anterior chamber invasion occurred in saline and MOX groups but in none of the FDC-containing groups, and perforations were absent in all FDC and PT treatments. CONCLUSIONS: FDC + PT was superior to monotherapies and to FDC + MOX, achieving frequent sterilization and preventing intraocular spread and corneal perforations. These data support PT alone or in combination with FDC as promising therapeutic candidates for the treatment of XDR P. aeruginosa keratitis.
Temporal association between aerosolized colistin use and colistin resistance in the ICU: a time-series analysis.
Kang W, Kang W, Son Y, Kim J, Cho K, et al. — 2026
BACKGROUND: Aerosolized colistin has been increasingly used to treat multidrug-resistant gram-negative infections, particularly in the intensive care unit (ICU), as an alternative to intravenous colistin, which is limited by nephrotoxicity and poor pulmonary penetration. Systemic colistin use has been linked to the emergence of resistance, but the impact of inhaled colistin on resistance development remains unclear. METHODS: We conducted a time-series analysis using monthly data from April 2014 to December 2023 in the ICUs of a 2700-bed tertiary-care hospital comprising 108 adult ICU beds. Monthly antibiotic use and the incidence of colistin-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii from respiratory specimens were analysed using vector autoregressive (VAR) or vector error correction models (VECMs), depending on the presence of stationarity and cointegration. RESULTS: In bivariate VAR analyses, aerosolized colistin use was positively associated with subsequent increases in colistin-resistant K. pneumoniae and A. baumannii, with significant effects observed across multiple lags. In multivariate VAR models including other antibiotic classes, the temporal association persisted for K. pneumoniae. Sensitivity analyses using VECM also showed significant associations for E. coli, K. pneumoniae, P. aeruginosa and A. baumannii. In an additional analysis of non-respiratory specimens, aerosolized colistin was also significantly associated with colistin-resistant A. baumannii. CONCLUSIONS: Aerosolized colistin use was temporally associated with increased resistance in major gram-negative pathogens, particularly K. pneumoniae and A. baumannii. These findings highlight the need for cautious use of inhaled colistin and support its inclusion in targeted antimicrobial stewardship efforts, given its potential contribution to the emergence of resistance.
CD1a-Mediated Presentation of Canonical Microbial Peptides to T Cells.
de Andrade Silva BJ, de Jong A, Fischbacher LA, Marques MAM, Legaspi A, et al. — 2026
Langerhans cells express the nonpolymorphic antigen-presenting molecule CD1a, positioning them as contributors to host immunity against in human leprosy. CD1a was originally shown to present non-canonical lipopeptide antigens such as dideoxymycobactin and chemically diverse hydrophobic ligands. Here, we generated CD4⁺ T cell lines from leprosy lesions that recognized in a CD1a-restricted manner. Unexpectedly, antigen recognition was protease-sensitive, prompting biochemical purification that identified two microbial protein antigens: LppX, a 25-kDa lipoglycoprotein, and Ag85A, a 30-kDa secreted protein with no known lipid modification. Recombinant proteins activated the corresponding T cell lines in a CD1a-dependent manner. Epitope mapping identified 12-mer peptides that fully reconstituted antigenicity, were conserved between and , and elicited robust, dose-dependent IFN-γ production and T cell proliferation, establishing that DNA-encoded, ribosomally translated peptides serve as CD1a-restricted cognate antigens. Biochemical analyses showed peptide binding to CD1a, supported by isoelectric focusing and surface plasmon resonance ( ∼75 μM for Ag85A). CD1a-peptide tetramers specifically stained cognate T cells, soluble CD1a was sufficient to present peptide antigen, and transfer of the LppX-specific TCR into naïve T cells restored antigen responsiveness. Using CD1a-peptide tetramers, we identified antigen-specific T cells enriched in patients undergoing reversal reactions compared with patients with lepromatous leprosy and healthy donors. The CD1a-restricted T cell lines secreted IFN-γ and IL-26, cytokines with established antimicrobial activity. Together, these findings demonstrate that CD1a can present canonical microbial peptides as part of a cell-mediated immune response in leprosy, extending the known spectrum of CD1a ligands. Because CD1a is nonpolymorphic and presents antigens to antimicrobial T cells, CD1a-peptide complexes may provide a broadly applicable platform for studying, detecting, and potentially targeting mycobacterial immunity.
Accelerated Mucopermeation and Penetration of the Polypeptide Antibiotic Colistin via Ionic Complexation with Polyphosphazene Carriers.
Stadler P, Kehrer S, Strasser P, Roschger C, Loretz B, et al. — 2026
The mucus barrier plays a vital protective role for nonkeratinized epithelia in the body, yet its complex structure poses a significant obstacle to effective noninvasive, topical drug delivery. Here, we synthesize chain-end-labeled poly-(α-glutamic acid) (PGA) and poly-[di-(carboxylatophenoxy)-phosphazene] (PCPP) and use an artificial pulmonary mucus to evaluate the mucopermeation of the polymers compared with the established mucus-penetrating polymer poly-(ethylene glycol) (PEG). The biodegradable polyacids PGA and PCPP exhibited mucus permeability similar to that of the biopersistent PEG, even at high polymer concentrations (up to 50 mg/mL). To enable drug loading, PGA and PCPP were further examined for their ability to electrostatically complex the antibiotic lipopeptide Colistin (Polymyxin E) at different polymer-to-Colistin ratios. Colistin binding studies in PBS confirmed effective encapsulation by both polymers with PCPP-Colistin complexes exhibiting the highest stability. Mucopermeation studies of the polymer-Colistin complexes revealed enhanced Colistin mucopermeation for both polyacids, with an enhanced effect observed for PCPP complexes. Furthermore, the broth microdilution assay revealed no differences in the minimum inhibitory concentrations (MICs) of Colistin, PGA-Colistin, or PCPP-Colistin. Overall, PCPP showed significantly superior performance due to its higher Colistin encapsulation efficiency, attributed to its unique chemical structure, thereby highlighting its potential as a biodegradable mucus-penetrating carrier for cationic therapeutic peptides.
Intact mass and peptide mapping approaches to characterize lipoprotein species of fHbp.
Long Z, Li M, Zhu X, Luo X, Wang B — 2026
Lipoproteins are promising vaccine candidates due to their bioactivity and self-adjuvanting properties, but complex lipid modifications essential for immunomodulatory function pose analytical challenges. Previous approaches combine peptide mass data from liquid chromatography-mass spectrometry (LC-MS) with lipid abundance data from gas chromatography-mass spectrometry, providing only indirect characterization. In this study, we developed a streamlined LC-MS strategy that combined high-resolution mass spectrometry with electron-transfer/higher-energy collision dissociation (EThcD) to enable direct and accurate characterization of lipid modifications at both intact protein and peptide levels. By integrating intact protein and peptide-level analysis, this approach provided detailed structural information on lipoprotein modifications. Using Neisseria meningitidis serogroup B factor H binding protein (fHbp) as a model, thirteen distinct lipid modifications were identified and relatively quantified, including seven tri-acylated and six di-acylated forms. The major fatty acid components (C16:0, C16:0, and C17:1) accounted for approximately 50% of the total fatty acids. The method also revealed differences in lipid distributions between manufacturers and changes during storage, with tri-acylated forms decreasing in favor of di-acylated species. This approach provides a robust and straightforward alternative for characterization, quality control, and stability assessment of lipoprotein-based vaccines and can also support comparability studies following manufacturing changes.